Xylometazoline is a potent, direct-acting sympathomimetic amine used as a topical nasal decongestant. It is a selective alpha-2 adrenergic receptor agonist, causing vasoconstriction of the dilated arterioles in the nasal mucosa. This leads to a rapid reduction in tissue hyperemia, edema, and nasal congestion. The 0.05% w/v concentration is specifically formulated for pediatric use and is a mainstay for symptomatic relief of nasal congestion in children in India.
Adult: Not applicable for 0.05% w/v. Adults should use 0.1% w/v formulation.
Note: 1. Blow nose gently to clear nostrils. 2. Tilt head slightly back. 3. For drops: Instill prescribed number of drops into each nostril. For spray: Insert tip into nostril, point away from nasal septum, and spray once while breathing in gently. 4. Avoid touching dropper/spray tip to nasal surfaces to prevent contamination. 5. Do not share the bottle.
Xylometazoline acts as a direct agonist on postsynaptic alpha-2 adrenergic receptors located on vascular smooth muscle within the nasal mucosa. This activation stimulates the G-protein coupled receptor, leading to increased intracellular calcium levels, resulting in smooth muscle contraction and vasoconstriction. This reduces blood flow to the engorged nasal venous sinusoids and turbinates, shrinking the swollen mucosa and improving nasal airway patency.
Pregnancy: Category C: Animal studies have shown adverse effects. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Should be used at the lowest effective dose for the shortest duration.
Driving: Unlikely to affect driving ability when used at recommended doses. However, systemic side effects like dizziness or blurred vision, if they occur, may impair ability.
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Tranylcypromine | Risk of severe hypertensive crisis due to potentiation of sympathomimetic effects. | Contraindicated |
| Tricyclic Antidepressants (TCAs) - e.g., Amitriptyline | May potentiate pressor effects of xylometazoline. | Major |
| Other Sympathomimetics (Oral decongestants - Pseudoephedrine, Phenylephrine) | Additive sympathomimetic effects, increasing risk of tachycardia and hypertension. | Major |
| Beta-blockers (non-selective) - e.g., Propranolol | Unopposed alpha-adrenergic stimulation may lead to severe hypertension and bradycardia. | Moderate |
| Methyldopa | May potentiate pressor response. | Moderate |
Same composition (Xylometazoline (0.05% w/v)), different brands: